Flex Pharma
Flex Pharma was a clinical-stage biopharmaceutical company that developed chemical neurostimulation technology (TRPV1/TRPA1 ion channel activators) for muscle cramps and spasticity, commercializing the HOTSHOT consumer sports product and the FLX-787 drug candidate.
- Company typePrivate
- Founded2014
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Flex Pharma does
Flex Pharma was a clinical-stage biopharmaceutical company founded in 2014 by Nobel Laureate Rod MacKinnon, M.D. (2003 Nobel Prize in Chemistry) and Harvard neurobiology professor Bruce Bean, Ph.D., both National Academy of Science members. The company's core technology centered on chemical neurostimulation through activation of Transient Receptor Potential (TRP) ion channels — specifically TRPV1 and TRPA1 — to reduce alpha-motor neuron hyperexcitability and thereby prevent or treat muscle cramps, spasms, and spasticity. Its two product lines were HOTSHOT, a direct-to-consumer sports shot for endurance athletes that used organic, non-GMO, NSF-Certified ingredients to activate TRP channels orally; and FLX-787, a proprietary drug candidate in clinical development targeting cramps, spasms, and spasticity associated with ALS, Multiple Sclerosis, and other neurological conditions.
The company generated revenue through two distinct streams: consumer product sales of HOTSHOT via its own e-commerce storefront (a product-led, one-time-purchase model), and prospective licensing/royalty economics from future commercialization of FLX-787. GTM was hybrid — direct-to-consumer for HOTSHOT targeting endurance athletes, and clinical-development-led for FLX-787 with presentations at AAN, ASENT, ACTRIMS, SFN, ACSM, and ECTRIMS medical conferences. The company was headquartered at 800 Boylston St., 24th Floor, Boston, MA, raised $40M in a 2014 funding round from investors including Bessemer Venture Partners, Spark Capital, Longwood Fund, and Lightstone Ventures, and was associated with NASDAQ ticker FLKS. Notably, as of 2025 the flex-pharma.com domain appears to have been repurposed as a Canadian online pharmacy affiliate selling generic erectile dysfunction medications (Cialis/Viagra), suggesting the original biotech operations have ceased.
Flex Pharma firmographics
Firmographics- Name
- Flex Pharma
- Legal name
- Flex Pharma, Inc.
- Website
- https://flex-pharma.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Flex Pharma was a clinical-stage biopharmaceutical company that developed chemical neurostimulation technology (TRPV1/TRPA1 ion channel activators) for muscle cramps and spasticity, commercializing the HOTSHOT consumer sports product and the FLX-787 drug candidate.
- Ownership category
- akta.pro rank
Flex Pharma industry classification
Industry- Product category
- Neuromuscular Therapeutics
- NAICS
- Sporting and Athletic Goods Manufacturing (33992), Food (Health) Supplement Retailers (456191)
- SIC
- Sporting & Athletic Goods, Nec (3949), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Sports Nutrition (Protein, Creatine, Pre-Workout/Intra-Workout) (CRADAGAA)
- akta.pro secondary industries
- Sports Medicine (HLAKALAB), Sports Nutrition & Performance Fueling (HSADAFAD)
Keywords
Where Flex Pharma is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Flex Pharma business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- HOTSHOT Consumer Product Sales: Direct-to-consumer sales of HOTSHOT, a sports nutrition product marketed to endurance athletes for preventing and treating muscle cramps. The product is NSF Certified for Sport, non-GMO Project Verified, and USDA Certified Organic.
- Drug Development (FLX-787): Development of pharmaceutical products for neuromuscular disorders including FLX-787 for cramps, spasms, and spasticity associated with neurological conditions such as ALS and Multiple Sclerosis.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Flex Pharma product offering
Product offeringCore offering
Flex Pharma develops treatments for muscle cramps and spasms grounded in proprietary chemical neurostimulation technology that activates TRPV1 and TRPA1 ion channels. Its commercial offering is HOTSHOT, a consumer sports nutrition shot marketed to endurance athletes for preventing and treating muscle cramps, while its clinical-stage offering is FLX-787, a drug candidate targeting cramps, spasms, and spasticity in neurological disorders such as ALS and Multiple Sclerosis.
Product overview
Flex Pharma is a biopharmaceutical company developing treatments for neuromuscular disorders with two distinct product lines: HOTSHOT, a consumer sports nutrition product marketed to endurance athletes for preventing muscle cramps; and FLX-787, a proprietary drug candidate in clinical development targeting muscle cramps and spasticity associated with neurological conditions through a novel chemical neurostimulation mechanism.
Differentiator
Problem solved
Functional benefit
Brands
- HOTSHOT: A proprietary sports shot with a kick, scientifically proven to prevent and treat muscle cramps. Non-GMO Project Verified, USDA Certified Organic product that is NSF Certified for Sport. Invented by Nobel Prize-winning neuroscientist Rod MacKinnon.
Products and services
- HOTSHOT A proprietary sports shot invented by Nobel Laureate Rod MacKinnon, scientifically proven to prevent and treat muscle cramps. Formulated with organic ingredients that activate TRP ion channels to boost neuromuscular performance, intended for endurance athletes such as runners, cyclists, and triathletes. The product is NSF Certified for Sport, non-GMO Project Verified, and USDA Certified Organic.
- FLX-787 A clinical-stage chemical neurostimulation drug candidate that topically activates TRPV1 and TRPA1 ion channels in the mouth, throat, esophagus, and stomach to inhibit neuronal circuits and reduce alpha-motor neuron hyperexcitability. Developed for the potential treatment of muscle cramps, spasms, and spasticity associated with neurological disorders including ALS and Multiple Sclerosis.
Companies that use Flex Pharma
Customer profileSegments2 records
Ideal customer profiles2 records
Flex Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Flex Pharma partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights3 records
Flex Pharma competitors and assessment
Company assessmentEmerging players
- LMNT (Elemental Labs): DTC electrolyte mix brand popular among endurance and strength athletes; recent entrant competing directly for HOTSHOT's premium-hydration positioning.
- Hyperice: Performance and recovery brand combining wearable tech and topicals for athletes; adjacent competitor pursuing the same endurance-athlete recovery and cramp-adjacent categories.
Direct peers
- SaltStick: Electrolyte capsule brand specifically marketed for muscle cramp prevention during endurance exercise; closest like-for-like competitor targeting the same cramp pain point.
- Pickle Juice Company: Pioneer of the pickle juice shot for exercise-associated muscle cramps; the most direct consumer-product competitor to HOTSHOT in the cramp-prevention category among endurance athletes.
- Skratch Labs: Sports nutrition brand making hydration and exercise products targeted at endurance athletes; competes with HOTSHOT for the same athlete wallet with broader product breadth.
- Nuun (Nuun & Company): Effervescent electrolyte tablet brand owned by Nestlé Health Science; competes in hydration/cramp-prevention within the endurance and everyday-active consumer category.
Broad incumbents
- Cytokinetics: Clinical-stage biopharmaceutical company developing muscle activators for neuromuscular diseases; comparable to the FLX-787 program in mechanism rationale (targeting motor-neuron hyperexcitability and muscle function) and indication focus.
- Acorda Therapeutics: Neurology-focused pharma with marketed spasticity therapies (e.g., dalfampridine for MS); relevant overlap with FLX-787's spasticity in MS patient population.
- Thorne (Thorne HealthTech): Premium supplement/nutraceutical brand with NSF Certified for Sport products; competes with HOTSHOT among credentialed, quality-conscious endurance athletes.
- Liquid IV (Unilever): Large-scale hydration/electrolyte brand now owned by Unilever; competes broadly in the endurance and active-lifestyle hydration category with substantially greater distribution and marketing spend.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Flex Pharma social profiles
Digital presenceFlex Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Flex Pharma leadership team
Management profileNumber of profiles
Profiles2 records
Flex Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Flex Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Flex Pharma
What does Flex Pharma do?
Flex Pharma develops treatments for muscle cramps and spasms grounded in proprietary chemical neurostimulation technology that activates TRPV1 and TRPA1 ion channels. Its commercial offering is HOTSHOT, a consumer sports nutrition shot marketed to endurance athletes for preventing and treating muscle cramps, while its clinical-stage offering is FLX-787, a drug candidate targeting cramps, spasms, and spasticity in neurological disorders such as ALS and Multiple Sclerosis.
Is Flex Pharma a public or private company?
Flex Pharma is a private company. It is classified as public and is currently operating.
When was Flex Pharma founded?
Flex Pharma was founded in 2014. It employs 11 to 50 people.
Where is Flex Pharma based?
Flex Pharma is headquartered in Boston, United States, in the North America region.
How does Flex Pharma make money?
Two revenue lines are on record. HOTSHOT Consumer Product Sales are the primary driver. The others are drug Development (FLX-787).
Who are Flex Pharma's main competitors?
Emerging players on record are LMNT (Elemental Labs) and Hyperice. Direct peers are SaltStick, Pickle Juice Company, Skratch Labs and Nuun (Nuun & Company). Broad incumbents are Cytokinetics, Acorda Therapeutics, Thorne (Thorne HealthTech) and Liquid IV (Unilever).
Does Flex Pharma have an API?
No public API is recorded for Flex Pharma.
What industry is Flex Pharma in?
Flex Pharma's product category is Neuromuscular Therapeutics. Its primary akta.pro industry code is CRADAGAA, Sports Nutrition (Protein, Creatine, Pre-Workout/Intra-Workout), with a secondary code of HLAKALAB, Sports Medicine. Its NAICS code is 33992 and its SIC code is 3949.